Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

ith serious autoimmune and inflammatory conditions."

Alba will lead worldwide development operations through the end of Phase 2 clinical trials in Celiac disease. The companies will share responsibility for Phase 3 clinical trial execution and for the pursuit of additional indications such as Crohn's disease. This will leverage Shire's regulatory and clinical experience, as well as its commercial infrastructure.

Michael Yasick, Shire's Senior Vice President and Gastrointestinal Global Business Unit Leader added:

"We are excited about this opportunity for Shire to expand its GI franchise beyond mesalamine-related products such as Lialda(TM) / MEZAVANT XL(R). We look forward to working closely with Alba on the development of these new therapies."

Dr. Paterson also noted that, "this partnership is another step in Alba's evolution as a biopharmaceutical company and provides a significant validation of our barrier function technology platform, specifically applied to gastrointestinal disease. The partnership will also enhance our ability to provide solutions for other inflammatory and immune related diseases, both acute and chronic."

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, both through the reduction of antigen presentation to the body's immune system and the inhibition of cytokine production. AT-1001 is orally formulated and is currently in Phase 2 studies for Celiac disease, a gastrointestinal autoimmune disease. INDs for oral AT-1001 in beta cell preservation (Type 1 Diabetes) and Crohn's disease have also been filed and cleared FDA review.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease modifying therapeutics to treat autoimmune and inflammatory di
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Next month, executives from clinical trial marketing firm BBK Worldwide ... Patient-Centered Clinical Trials 2014 , to be held at ... September 4-5. Patient recruitment experts Bonnie A. Brescia , ... share insights on the benefits of employing an effective patient ... media to mobile apps – can be used to drive ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge in ... 2014 symposium. Marking its 46th year, the annual ... 14-17 September. The event is sponsored by SPIE, ... The premier conference for basic and applied issues which ... will engage researchers and engineers from numerous industries and ...
(Date:8/28/2014)... August 28, 2014 Whitehouse Laboratories is ... term partnership with PTI Inspection Systems that ... state of the art leak testing method development and ... instruments currently available. As part of this agreement, Whitehouse ... Voltage Leak Detection Instrument developed and manufactured by ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... drugs for the treatment of human viral,and other ... third quarter and nine months ended September 30, ... and marketable,securities totaled approximately $60.1 million., 2008 ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that its Analyst Day ... 2008, will be webcast live on the investor relations ... senior management will review the company,s business,strategy, marketing plan ... on Wednesday, November 5, 2008 beginning at,approximately 12:30 p.m. ...
... Cytochroma today announced the,appointment of Ulrik Spork to its ... the Company,s Board and replaces Dr. Soren Schifter,who is ... unchanged at,six members., "We are very pleased to ... drawing on his expertise and experiences as we continue ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 5Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 6Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 7Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... our body have a system that can handle cellular ... mechanism is called autophagy and literally means "self-eating". Many ... and the increased release of building blocks equip the ... them resistant towards treatment. "We have discovered ...
... AMHERST, Mass. Today in Washington, D.C., Secretary ... of Massachusetts Amherst has been chosen to lead a ... center, the Northeast Climate Science Center through a five-year, ... other agencies by studying the effects of climate change ...
... Researchers at Stanford,s Jasper Ridge Biological Preserve often ... to the occasional deer carcass covered with leaves. But ... feline. Now, images captured by remote wildlife cameras ... make regular visits to Stanford,s 1,189-acre preserve in the ...
Cached Biology News:Small molecules can starve cancer cells 2UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center 2UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center 3Learning to live in mountain lion country 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known rice microRNAs ...
... the research-grade spectrofluorometer with a minimum 1 ... ratio 200 or greater for the Raman ... designed to keep in mind in order ... stopped-flow, titration, or anisotropic measurements. ,The FP-6500 ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
Biology Products: